.svg)
Oral Thin Film formulations have become a cornerstone in oral drug delivery, valued for their ability to deliver active pharmaceutical ingredients efficiently and reliably. Unlike other traditional oral dosage formulations such as tablets or capsules, these thin, flexible strips dissolve rapidly in the mouth. This allows the medication to be absorbed faster either through the oral mucosa or the gastrointestinal tract. Their design addresses persistent challenges in patient adherence, particularly among pediatric, geriatric, and dysphagic populations, while providing consistent dosing and rapid onset of action.
The growing adoption of OTF formulations underlines a broader shift in pharmaceutical manufacturing. The industry is becoming more patient-centric and precision-oriented. They offer manufacturers the ability to optimize release profiles, combine multiple APIs, and tailor formulations to specific therapeutic needs.
By 2028, Oral Thin Film formulations are projected to reach $7.65 billion, growing at a CAGR of 13.6%. (Source: Oral Thin Films - Global Strategic Business Report, September 2025). The focus now remains on balancing scalable production with clinical efficacy, regulatory compliance, and enhanced patient outcomes.
Several factors are fueling the demand for Oral Thin Films, such as:
Regionally, North America leads in adoption due to strong healthcare infrastructure and regulatory support. Asia-Pacific is witnessing rising momentum, driven by expanding generic drug manufacturers in India, improving healthcare access, and growing demand for patient-friendly dosage forms (Source: Biotechnology Advances, Volume 73, 2024).
The evolution of OTF formulation is being accelerated by printing technologies and additive manufacturing:
These technological innovations not only enhance bioavailability but also provide pharmaceutical manufacturers with flexibility in product development, scaling, and compliance with global quality standards.
For Patients
These advantages make OTF formulations particularly suitable for medications that require rapid onset, such as antiemetics, CNS drugs, or analgesics.
For Healthcare Providers
OTF formulations also bridge patient-centric design with operational efficiency, reinforcing their growing appeal across therapeutic areas.
For further insight into patient-centric design principles, see our previous blog on Oral Dosage Forms and Patient-Centric Design.
Recent advances are addressing longstanding limitations of oral drug delivery:
These innovations make OTFs a versatile solution for chronic conditions, acute therapies, and combination drugs, while maintaining manufacturing scalability and regulatory compliance.
Several macro factors are accelerating OTF formulation adoption:
The COVID-19 pandemic underscored the importance of dosage forms that patients can administer themselves, with minimal need for healthcare facility visits or caregiver support.
Oral Thin Film formulations have emerged as a particularly compelling option, offering rapid, convenient, and discreet drug delivery without requiring water. For patients managing chronic conditions, pain, or mental health therapies, this ease of use reduced barriers to adherence and supported continuity of care during periods of restricted mobility.
Oral Thin Film formulations are poised to redefine how medications are delivered. Advances in 3D and inkjet printing are enabling precise, multilayered films that can combine multiple active ingredients while maintaining stability and uniformity. This translates to the ability to tailor dosage forms to specific patient needs, whether for pediatrics, geriatrics, or complex combination therapies.
At the same time, AI-driven formulation design is beginning to optimise key parameters such as dissolution rates, release profiles, and patient adherence patterns. Integrating predictive modeling with real-time manufacturing data allows pharmaceutical manufacturers to refine products faster while maintaining stringent regulatory standards.
Furthermore, quality control is becoming more dynamic. In-line monitoring and analytics help ensure consistency across batches, reducing risks and accelerating time-to-market.
By 2028, these innovations could result in Oral Thin Film formulations supporting personalised therapies, and improving bioavailability as well as patient experience, while allowing global pharmaceutical companies to respond to evolving healthcare demands with flexibility and confidence.
ZIM Laboratories Limited is a therapy-agnostic and innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
